The worldwide market for lifestyle-associated cancer epidemiology is expected to expand rapidly, owing to the rising global awareness of modifiable risk factors such as tobacco use, obesity, poor diet, alcohol consumption, and physical inactivity, which together contribute significantly to cancer incidence. Health organizations, along with research institutions, are investing in enhanced surveillance, behavioral risk monitoring, cancer registries, and prevention strategies to address the growing burden of preventable cancers. In recent years, the World Health Organization and several national bodies have emphasized data-driven epidemiology. These initiatives support targeted interventions, policy measures, and screening programs. Additionally, the widespread adoption of digital epidemiology tools, precision prevention approaches, and AI-powered analytics is fueling the demand for robust epidemiology infrastructure worldwide.
Lifestyle-Associated Cancer Epidemiology Market Trends & Forecast
According to a research study published by Knowledge Sourcing Intelligence (KSI), the lifestyle-associated cancer epidemiology market will expand from USD 8.96 billion in 2026 to USD 13.12 billion in 2031 at a CAGR of 7.9% during the forecast period.
Lifestyle-Associated Cancer Epidemiology revolves around the study and surveillance of cancers linked to modifiable behavioral and environmental risk factors, which are essential for providing public health systems, policymakers, and researchers with data to identify trends, assess burdens, and, as a result, design effective prevention and early intervention strategies. The key ideas which are focused upon include tracking incidents related to obesity, alcohol, tobacco, dietary patterns, as well as physical inactivity across several cancer types such as breast cancer, lung cancer, liver cancer, and others. In this particular space, technological approaches consist of advanced cancer registries as well as population-level behavioral surveillance with AI-driven predictive modeling and genomic integration for risk stratification.
Furthermore, several global efforts, including the World Health Organization's frameworks for non-communicable disease prevention and National Cancer Control programs, are playing an efficient role in the continuation of driving investments in epidemiological capacity. Not only this, but rising urbanization, incidentally, lifestyles, and dietary shifts are also amplifying the need for scalable surveillance systems.
Request a free sample copy or view the report summary: Lifestyle-Associated Cancer Epidemiology Market Report
Lifestyle-Associated Cancer Epidemiology Market Report Highlights
WHO and partners strengthened global tobacco control and obesity prevention frameworks in 2025 as part of broader non-communicable disease initiatives.
National Cancer Institute expanded funding for behavioral oncology and lifestyle-associated cancer epidemiology research programs in early 2026.
CDC enhanced integration of behavioral risk factor surveillance with cancer registry data across multiple states and conditions.
IARC advanced carcinogen classification and population-level risk assessment for lifestyle factors in ongoing 2025-2026 initiatives
Lifestyle-Associated Cancer Epidemiology Market Growth Drivers and Restraints
Growth Drivers:
The Rising prevalence of key factors such as tobacco use, obesity, and alcohol consumption is regarded as primary drivers which are playing an important role in the increasing demand for detailed epidemiological tracking and prevention-focused data. Obesity is regarded as the core issue that influences inflammatory and hormonal pathways that are linked to multiple cancers, whereas tobacco use remains one of the leading causes of lung cancer. In this regard, public health campaigns and regulatory efforts are boosting the need for surveillance.
The expansion of cancer registries, AI analytics and digital epidemiology platforms is supporting the real-time monitoring and predictive modeling for these cancer types. A governmental research organization is investing in harmonized datasets, a precision prevention program integrating behavioral and genomic risks, and policy-driven initiatives that could be essential in reducing the cancer burden. Furthermore, one of the major growth drivers revolves around the national and international emphasis on preventive healthcare, which includes screening programs and behavioral interventions.
Restraints:
Uneven or fragmented cancer registry infrastructure, followed by the inconsistency of data quality across multiple regions, with limited screening participation, is hindering the comprehensive surveillance of cancer types. Additionally, the low adherence to behavioral interventions and challenges to equitable access are also preventing resources, resulting in constrained outcomes.
Lifestyle-Associated Cancer Epidemiology Market Growth Key Development
April 2026: Union for International Cancer Control expanded international collaboration initiatives supporting prevention-focused cancer control policies and epidemiological data harmonisation.
February 2026: The National Cancer Institute increased funding support for behavioural oncology and lifestyle-associated cancer epidemiology research programs.
June 2025: The World Health Organisation expanded its global tobacco cessation framework under international non-communicable disease prevention initiatives to reduce the smoking-associated cancer burden.
Lifestyle-Associated Cancer Epidemiology Market Growth Segmentation
Knowledge Sourcing Intelligence has segmented the Lifestyle-Associated Cancer Epidemiology Market Growth based on cancer type, risk factor, age group, by healthcare setting, and region:
Lifestyle-Associated Cancer Epidemiology Market By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Skin Cancer
Lifestyle-Associated Cancer Epidemiology Market By Risk Factor
Tobacco Use
Alcohol Consumption
Obesity
Dietary Factors
Physical Inactivity
Lifestyle-Associated Cancer Epidemiology Market By Age Group
Pediatric
Adult
Geriatric
Lifestyle-Associated Cancer Epidemiology Market By Healthcare Setting
Hospitals
Cancer Centers
Preventive Care Clinics
Lifestyle-Associated Cancer Epidemiology Market By Region
North America
USA
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Others
Asia Pacific
China
India
Japan
South Korea
Australia
Thailand
Others
South America
Brazil
Argentina
Others
Middle East and Africa (MEA)
Saudi Arabia
UAE
Others
Lifestyle-Associated Cancer Epidemiology Market Key Players
World Health Organization
International Agency for Research on Cancer
American Cancer Society
National Cancer Institute
Centers for Disease Control and Prevention
Cancer Research UK
Union for International Cancer Control
Globocon
Need specialized data cuts or competitive intelligence?
Our analyst team provides bespoke market sizing, supplier audits, and country-level feasibility reports tailored to your enterprise roadmap.
Speak With an Industry Analyst →Lifestyle-Associated Cancer Epidemiology Market - Strategic Insights and Forecasts (2026-2031)
Lifestyle-associated cancers are becoming a major global epidemiological burden due to increasing exposure to preventable behavioral and environmental risk factors. The report focuses on the relationship between tobacco use, alcohol consumption, obesity, dietary patterns, and physical inactivity with rising cancer incidence. Demand for epidemiological surveillance is increasing as healthcare systems are facing growing pressure from preventable cancers. Delayed behavioral intervention constrains reduction in disease burden, which is increasing long-term healthcare costs. Governments and international organizations are expanding cancer prevention programs and surveillance infrastructure. This expansion is strengthening population-level monitoring and prevention strategies.
Ask an Industry Analyst
Have questions regarding this briefing or market projections? Inquire with our sector lead.
Related Press Releases
View All →
ADC Manufacturing & CDMO Market is expected to reach USD 10.49 billion by 2031
Aug 7, 2026
Psycho-Oncology Digital Health Market is anticipated to surpass USD 290.01 million in 2031 at a CAGR of 8.5%
Jul 30, 2026
Intratumoral Injection Therapy Market is expected to reach USD 630.39 million by 2031
Jul 24, 2026
Palliative Care in Oncology Market is expected to reach USD 244.1 billion by 2031
Jul 22, 2026
Oncology Drug Resistance Testing Market is projected to reach USD 3.41 billion in 2031 at a CAGR of 6.6 %
Jul 20, 2026More Press Releases
TROP-2 Targeted Therapy Market is anticipated to surpass USD 3.29 billion in 2031 at a CAGR of 8.6 %
The TROP-2 Targeted Therapy market is expanding rapidly due to increasing precision oncology adoption, rising cancer prevalence, and growing use of antibody-drug conjugates. North America leads the market, while Asia Pacific shows the fastest growth. Continuous clinical trials, regulatory approvals, and strategic collaborations are accelerating innovation and commercial adoption worldwide.
Second Primary Cancer Prevention Market is expected to reach USD 24.7 billion by 2031
The Second primary cancer prevention refers to strategies aimed at reducing the risk of developing a new, unrelated cancer in individuals with a prior cancer diagnosis. Growing cancer survivorship, advances in treatment, and increasing awareness of long-term health outcomes have heightened the importance of prevention and surveillance programs. Key approaches include routine screening, genetic risk assessment, lifestyle modification, and long-term follow-up care. Government agencies and healthcare organisations increasingly emphasise survivorship care plans and evidence-based screening protocols to detect new malignancies at earlier stages. Continued investments in early detection technologies and personalised risk assessment are expected to support advancements in second primary cancer prevention.
Synthetic Lethality Drug Market is expected to reach USD 4.31 billion by 2031
The worldwide market for Synthetic Lethality Drug Market is expected to witness significant growth due to an increasing adoption of precision oncology approaches as well as the rising prevalence of genetically driven cancers. Synthetic lethality-based therapies are considered efficient as they are transforming cancer treatment by targeting tumor-specific genetic vulnerabilities, which minimizes damage to healthy cells. Multiple growing investments in genomic research, next-generation sequencing technologies, and biomarker discovery are also accelerating their identification of novel synthetic legal targets. Additionally, increasing regulatory support for targeted therapies, advancements in companion diagnostics, as well as expansion of clinical trial activity are factors that are contributing to market expansion.